FDA Approves Natera's Signatera CDx for Bladder Cancer Treatment Guidance — Natera, Inc.

Event summary

FDA approved Signatera CDx as a companion diagnostic for adjuvant atezolizumab (Tecentriq®) in muscle-invasive bladder cancer (MIBC).
Approval follows the IMvigor011 trial, showing MRD-positive patients benefited from immunotherapy while MRD-negative patients achieved 97% 2-year OS without treatment.
Signatera CDx is the first FDA-approved companion diagnostic for blood-based minimal residual disease (MRD) in cancer care.
Natera's test is supported by over 185 peer-reviewed publications and Medicare coverage across multiple cancer types.

The big picture

This approval marks a significant shift toward MRD-guided cancer care, where treatment decisions are increasingly personalized. The IMvigor011 trial results underscore the potential of Signatera CDx to improve outcomes by identifying patients who benefit most from immunotherapy while sparing others unnecessary treatment. Natera's leadership in blood-based MRD testing positions it at the forefront of the precision oncology revolution.

What we're watching

Adoption Pace: How quickly Signatera CDx will be integrated into standard MIBC treatment protocols following FDA approval.
Market Expansion: Whether Natera can leverage this approval to expand Signatera's use in other cancer types beyond bladder cancer.
Competitive Response: How competitors in the precision oncology space will react to Natera's FDA milestone and potential market share impact.